- Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
- Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
- Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
- Ocugen to Present at BIO International Convention 2024
- Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
- Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
- Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
- Ocugen Provides Business Update with First Quarter 2024 Financial Results
- Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
- Ocugen to Present at May 2024 Investor Conferences
More ▼
Key statistics
On Wednesday, Ocugen Inc (OCGN:NAQ) closed at 1.64, -22.09% below its 52-week high of 2.11, set on Mar 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.59 |
---|---|
High | 1.70 |
Low | 1.57 |
Bid | 1.58 |
Offer | 1.63 |
Previous close | 1.61 |
Average volume | 10.41m |
---|---|
Shares outstanding | 257.35m |
Free float | 253.28m |
P/E (TTM) | -- |
Market cap | 414.34m USD |
EPS (TTM) | -0.2348 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼